These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 5997620

  • 1. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S, Philippidis P, Drossos C, Economidis J.
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract] [Full Text] [Related]

  • 2. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G, Cazzavillan M, Chisesi T, Battista R, Barbui T, Dini E.
    Minerva Med; 1978 Mar 17; 69(13):811-21. PubMed ID: 643223
    [No Abstract] [Full Text] [Related]

  • 3. Desferal therapy in iron storage disease.
    Thompson RB, Owen DM, Bell WN.
    Am J Med Sci; 1967 Apr 17; 253(4):453-60. PubMed ID: 6021380
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical and metabolic research on treatment with desferrioxamine B in various hemosiderotic erythrocyte diseases].
    Cimino R, Quattrin N.
    Clin Ter; 1965 Jul 15; 34(1):3-32. PubMed ID: 5840761
    [No Abstract] [Full Text] [Related]

  • 5. [Desferrioxamine-B in the diagnosis of hemosiderotic states and in the therapy of thalassemia. Apropos of 2 cases].
    De Luca G, Faelli U, Petrussa I.
    Minerva Pediatr; 1966 Oct 27; 18(32):1920-5. PubMed ID: 5993655
    [No Abstract] [Full Text] [Related]

  • 6. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L, Ferrara M, Galdo Capotorti M.
    Pediatria (Napoli); 1978 Mar 31; 86(1):69-76. PubMed ID: 683795
    [No Abstract] [Full Text] [Related]

  • 7. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
    el-Gholmy A, Khalifa AS, Rahman YA, el-Bagoury I.
    J Trop Med Hyg; 1969 Jan 31; 72(1):22-6. PubMed ID: 5773810
    [No Abstract] [Full Text] [Related]

  • 8. [Use of desferal in treatment of sideroses of different origin. (Literature review)].
    Turbina NS.
    Probl Gematol Pereliv Krovi; 1968 Jul 31; 13(7):47-52. PubMed ID: 4898933
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC.
    Trans Assoc Am Physicians; 1977 Jul 31; 90():335-41. PubMed ID: 611665
    [No Abstract] [Full Text] [Related]

  • 10. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E, Bianco I, Masi M.
    Policlinico Prat; 1967 Dec 11; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract] [Full Text] [Related]

  • 11. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R, Colebatch JH, Gordon P, Ekert H.
    Arch Dis Child; 1974 Aug 11; 49(8):621-6. PubMed ID: 4278421
    [Abstract] [Full Text] [Related]

  • 12. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A, Raybaud C, Bernard PJ, Aquaron R, Passeron P.
    Mars Med; 1967 Aug 11; 104(4):331-7. PubMed ID: 5621537
    [No Abstract] [Full Text] [Related]

  • 13. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
    Pippard MJ.
    Acta Haematol; 1987 Aug 11; 78(2-3):206-11. PubMed ID: 3120473
    [Abstract] [Full Text] [Related]

  • 14. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N, Ullrich D, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1985 Nov 29; 110(48):1848-51. PubMed ID: 4064938
    [Abstract] [Full Text] [Related]

  • 15. [Use of desferrioxamine B in normal subjects and in patients with increased iron storage].
    Muranda M, Velasco M, Giménez E, Ruiz J, Bastías E, Rodriguez J, Etcheverry R, Guzmán C, Regonesi C, Janklevich S.
    Rev Med Chil; 1965 Apr 29; 93(4):127-33. PubMed ID: 5832943
    [No Abstract] [Full Text] [Related]

  • 16. [Desferrioxamine in patients with hemochromatosis and hemosiderosis].
    Maspes V, Tamigaki M, Gomes ZJ, Jamra M.
    Rev Hosp Clin Fac Med Sao Paulo; 1966 Apr 29; 21(4):181-95. PubMed ID: 5918167
    [No Abstract] [Full Text] [Related]

  • 17. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N, Kijewski H, König R, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1984 Nov 02; 109(44):1682-5. PubMed ID: 6489181
    [Abstract] [Full Text] [Related]

  • 18. Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine.
    Cumming RL, Goldberg A, Morrow J, Smith JA.
    Lancet; 1967 Jan 14; 1(7481):71-4. PubMed ID: 4163055
    [No Abstract] [Full Text] [Related]

  • 19. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA.
    J Lab Clin Med; 1993 Jul 14; 122(1):48-54. PubMed ID: 8320490
    [Abstract] [Full Text] [Related]

  • 20. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML, Lang JM, Bergerat JP, Giron C, Oberling F, Mayer S.
    Nouv Rev Fr Hematol (1978); 1984 Jul 14; 26(5):317-21. PubMed ID: 6334273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.